Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma

Mara De Martino; Oscar Padilla; Camille Daviaud; Cheng Chia Wu; Robyn D. Gartrell; Claire Vanpouille-Box

doi:10.3389/fonc.2021.671044

Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma

Mara De Martino
, Oscar Padilla
, Camille Daviaud
, Cheng Chia Wu
, Robyn D. Gartrell
, Claire Vanpouille-Box

Research output: Contribution to journal › Review article › peer-review

Abstract

Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.

Original language	English (US)
Article number	671044
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.671044
State	Published - May 20 2021
Externally published	Yes

Keywords

adjuvanticity
antigenicity
glioblastoma
immunosuppression
immunotherapy
radiotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2021.671044

Cite this

@article{b3b00afa68af444093d06354c4bedce3,

title = "Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma",

abstract = "Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.",

keywords = "adjuvanticity, antigenicity, glioblastoma, immunosuppression, immunotherapy, radiotherapy",

author = "\{De Martino\}, Mara and Oscar Padilla and Camille Daviaud and Wu, \{Cheng Chia\} and Gartrell, \{Robyn D.\} and Claire Vanpouille-Box",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 De Martino, Padilla, Daviaud, Wu, Gartrell and Vanpouille-Box.",

year = "2021",

month = may,

day = "20",

doi = "10.3389/fonc.2021.671044",

language = "English (US)",

volume = "11",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma

AU - De Martino, Mara

AU - Padilla, Oscar

AU - Daviaud, Camille

AU - Wu, Cheng Chia

AU - Gartrell, Robyn D.

AU - Vanpouille-Box, Claire

PY - 2021/5/20

Y1 - 2021/5/20

N2 - Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.

AB - Glioblastoma (GBM) is among the most aggressive of brain tumors and confers a dismal prognosis despite advances in surgical technique, radiation delivery methods, chemotherapy, and tumor-treating fields. While immunotherapy (IT) has improved the care of several adult cancers with previously dismal prognoses, monotherapy with IT in GBM has shown minimal response in first recurrence. Recent discoveries in lymphatics and evaluation of blood brain barrier offer insight to improve the use of ITs and determine the best combinations of therapies, including radiation. We highlight important features of the tumor immune microenvironment in GBM and potential for combining radiation and immunotherapy to improve prognosis in this devastating disease.

KW - adjuvanticity

KW - antigenicity

KW - glioblastoma

KW - immunosuppression

KW - immunotherapy

KW - radiotherapy

UR - https://www.scopus.com/pages/publications/85107295821

UR - https://www.scopus.com/pages/publications/85107295821#tab=citedBy

U2 - 10.3389/fonc.2021.671044

DO - 10.3389/fonc.2021.671044

M3 - Review article

AN - SCOPUS:85107295821

SN - 2234-943X

VL - 11

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 671044

ER -

Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this